Ambrosia Biosciences Inc.
United States
- Boulder, CO
- 21/08/2024
- Series A
- $16,000,000
Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
- Industry Biotechnology Research
- Website https://ambrosiabiosciences.com/
- LinkedIn https://www.linkedin.com/company/ambrosia-biosciences/
Related People
Nick TraggisFounder
United States -
Boulder, Colorado
I am a CEO, mentor, and dealmaker with diverse experience in biotech, optics/photonics, and other high-tech physical industries. With a career foundation of technical problem solving and leadership skills, I am able to communicate effectively across the boardroom, laboratory, and shop floor as needed.
CAREER HIGHLIGHTS
• Led or advised 7 M&A transactions with >$500M in deal value creation
• >20 technology licensing/IP transfer agreements completed
• >$130M in financing raised from equity, debt, and non-dilutive(government) sources.
• Led the design and construction of 4 U.S. based manufacturing facilities within the optics and medical device industries.
Lula Commerce | $8,000,000 | (Oct 29, 2025)
Flamingo(US) | $2,200,000 | (Oct 29, 2025)
CoreStory | $32,000,000 | (Oct 29, 2025)
Cylerity | $4,000,000 | (Oct 29, 2025)
Sweatpals | $12,000,000 | (Oct 29, 2025)
Polygraf AI | $9,000,000 | (Oct 29, 2025)
EPIC(US) | $10,000,000 | (Oct 29, 2025)
iPNOTE - Your Virtual IP Paralegal | $1,000,000 | (Oct 29, 2025)
Wild Moose | $7,000,000 | (Oct 29, 2025)
UPTIQ | $12,000,000 | (Oct 29, 2025)
Spacial | $10,000,000 | (Oct 29, 2025)
Syllo | $30,000,000 | (Oct 29, 2025)